R-CHOP Dosing for Diffuse Large B-Cell Lymphoma

Standard Dosing by Age and Risk Group

The standard R-CHOP-21 regimen consists of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered every 21 days, as recommended by the European Society for Medical Oncology 1, 2, 3
For patients aged ≤60 years with good risk (aaIPI 0-1), six cycles of R-CHOP-21 with eight total doses of rituximab is the current standard, according to the National Comprehensive Cancer Network 1, 2
Alternative treatment for early stage (I-II) includes three cycles of R-CHOP plus involved field radiation, as suggested by the American Society of Clinical Oncology 1
For patients aged 60-80 years, eight cycles of R-CHOP-21 with eight doses of rituximab administered every 21 days is the standard, based on guidelines from the European Society for Medical Oncology 1, 2, 3

Vincristine should be administered at 1.4 mg/m² intravenously (maximum dose capped at 2 mg) on day 1, due to neurotoxicity concerns, as recommended by the American Society of Clinical Oncology 4

Full weight-based dosing should be used for all chemotherapy agents in obese patients, without arbitrary caps or reductions, as recommended by the National Comprehensive Cancer Network 4
The only exception is vincristine, which is capped at 2 mg regardless of body surface area due to neurotoxicity, according to the American Society of Clinical Oncology 4

Dose reductions due to hematological toxicity should be avoided in patients treated with curative intent, as recommended by the European Society for Medical Oncology 1, 2, 3
Febrile neutropenia justifies prophylactic use of granulocyte colony-stimulating factor rather than dose reduction, based on guidelines from the National Comprehensive Cancer Network 1, 2, 3

PCP prophylaxis with sulfamethoxazole/trimethoprim (or equivalent) is mandatory throughout treatment and for 6-12 months after rituximab completion, as recommended by the Centers for Disease Control and Prevention 5
Herpes virus prophylaxis with acyclovir or equivalent is also mandatory, according to the Infectious Diseases Society of America 5
Irradiation of all blood products is necessary to prevent transfusion-associated GVHD in patients receiving rituximab-containing regimens, as recommended by the American Association of Blood Banks 5